Neurologic Manifestations of Glioblastoma Multiforme Medication

Updated: Nov 09, 2015
  • Author: ABM Salah Uddin, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print
Medication

Medication Summary

The goals of pharmacotherapy for glioblastoma multiforme (GBM) are to reduce morbidity and to prevent complications.

Next:

Alkylating agents

Class Summary

This oral alkylating agent has been approved for newly diagnosed GBM and recurrent anaplastic astrocytomas.

Temozolomide (Temodar)

Oral alkylating agent converted to MTIC at physiologic pH; 100% bioavailable; approximately 35% crosses blood-brain barrier. Indicated for GBM combined with radiotherapy. Significant overall survival was demonstrated in patients treated with temozolomide and radiation compared with radiotherapy alone.

Previous
Next:

Cytotoxic agents

Class Summary

Local chemotherapy with carmustine (BCNU) wafers (Gliadel wafers) significantly prolongs survival in patients with newly diagnosed primary malignant glioma.

Carmustine

Gliadel is a small wafer that contains the chemotherapeutic drug carmustine, or BCNU. The wafer is designed to release the drug slowly over a period of 2-3 wk after placed in tumor bed. Up to 8 Gliadel wafers are implanted in the cavity, slowly delivering BCNU directly to tumor site.

Previous